Navigation Links
Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model
Date:11/13/2012

PHILADELPHIA - The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a mutation in the Myc gene.

Accordingly, depriving cells of glutamine selectively induces programmed cell death in cells overexpressing mutant Myc.

Using Myc-active neuroblastoma cancer cells, a team led by Howard Hughes Medical Institute (HHMI) investigator M. Celeste Simon, Ph.D., scientific director for the Abramson Family Cancer Research Institute (AFCRI), identified the proteins PUMA, NOXA, and TRB3 as executors of the glutamine-starved cells. These three proteins represent a downstream target in the Myc pathway at which to aim drugs. Roughly 25 percent of all neuroblastoma cases are associated with Myc-active cells.

The findings appear in this week's issue of Cancer Cell. Simon is also a professor of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. The Penn team collaborated with colleagues from The Children's Hospital of Philadelphia (CHOP) John Maris and Michael Hogarty.

"These findings come from studies of fundamental cellular pathways and would not have been discovered without ongoing support for basic research," notes Simon. "Translational research is very important, but equal emphasis on basic research of processes such as cellular metabolism is critical for the ultimate cure of cancer."

Glutamine depletion in Myc-mutant cells induces cell death through a complicated series of molecular switches involving the three protein executors and the DNA-binding protein ATF4. Knowing this, the team showed that either agonists of ATF4 or inhibitors of glutamine metabolism potently caused cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice. Drugs in these two classes have been approved by the Food and Drug Administration and are being tested in clinical trials for other disorders.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Targeting inflammation to treat depression
2. Targeting inflammation to prevent, treat cancers
3. New targeting technology improves outcomes for patients with atrial fibrillation
4. IBN discovers human neural stem cells with tumor targeting ability
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. G proteins regulate remodelling of blood vessels
7. Salk study finds diabetes raises levels of proteins linked to Alzheimers features
8. Toward medicines that recruit the bodys natural disease-fighting proteins
9. Enzymes implicated in disease processes attack one another instead of harming body proteins
10. New regulatory mechanism discovered in cell system for eliminating unneeded proteins
11. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... product is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound ...
(Date:1/19/2017)... ... 19, 2017 , ... WholeHealth is announcing their participation in ... Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in the ... , “We know it’s easy to get carried away when you’re having ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dermatologist by the American Board of Dermatology and fellowship trained Mohs and cosmetic ... National Institutes of Health, Dr. Li completed his internship in internal medicine at ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is ... modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare ... single page, maximizing usability and improving efficiency significantly for users – a first ...
(Date:1/19/2017)... ... 19, 2017 , ... Students interested in video can get a jump start ... will earn a $1,000 scholarship and have his or her video posted on the ... is May 31, with the winner announced on June 9. , The competition is ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)...   Synthetic Biologics, Inc. (NYSE MKT: ... to preserve the microbiome to protect and restore ... initiate a Phase 2b/3 adaptive pivotal trial for ... designed to reduce methane production by certain microorganisms ... treat the underlying cause of irritable bowel syndrome ...
Breaking Medicine Technology: